PURPOSE: Prostate specific antigen is a glycoprotein found almost exclusively in normal and neoplastic prostate cells. Prostate specific antigen doubling time, or the change in prostate specific antigen over time, has emerged as a useful predictive marker for assessing disease outcome in patients with prostate cancer. It is important to agree on definitions and values for the calculation of prostate specific antigen doubling time, and to develop a common approach to outcome analysis and reporting. MATERIALS AND METHODS: In September 2006 a conference was held at the National Cancer Institute in Bethesda, Maryland to define these parameters and develop guidelines for their use. RESULTS: The Prostate Specific Antigen Working Group defined criteria regarding prostate specific antigen doubling time including the calculation of prostate specific antigen doubling time, evidence to support prostate specific antigen doubling time as a predictive factor in the setting of biochemical recurrence and the use of prostate specific antigen doubling time as a stratification factor in clinical trials. CONCLUSIONS: We propose that investigators calculate prostate specific antigen doubling time before enrolling patients in clinical studies and calculate it as an additional measurement of therapeutic activity. We believe we have developed practical guidelines for the calculation of prostate specific antigen doubling time and its use as a measurement of prognosis and outcome. Furthermore, the use of common standards for prostate specific antigen doubling time in clinical trials is important as we determine which treatments should progress to randomized trials in which "hard" end points such as survival will be used.
PURPOSE:Prostate specific antigen is a glycoprotein found almost exclusively in normal and neoplastic prostate cells. Prostate specific antigen doubling time, or the change in prostate specific antigen over time, has emerged as a useful predictive marker for assessing disease outcome in patients with prostate cancer. It is important to agree on definitions and values for the calculation of prostate specific antigen doubling time, and to develop a common approach to outcome analysis and reporting. MATERIALS AND METHODS: In September 2006 a conference was held at the National Cancer Institute in Bethesda, Maryland to define these parameters and develop guidelines for their use. RESULTS: The Prostate Specific Antigen Working Group defined criteria regarding prostate specific antigen doubling time including the calculation of prostate specific antigen doubling time, evidence to support prostate specific antigen doubling time as a predictive factor in the setting of biochemical recurrence and the use of prostate specific antigen doubling time as a stratification factor in clinical trials. CONCLUSIONS: We propose that investigators calculate prostate specific antigen doubling time before enrolling patients in clinical studies and calculate it as an additional measurement of therapeutic activity. We believe we have developed practical guidelines for the calculation of prostate specific antigen doubling time and its use as a measurement of prognosis and outcome. Furthermore, the use of common standards for prostate specific antigen doubling time in clinical trials is important as we determine which treatments should progress to randomized trials in which "hard" end points such as survival will be used.
Authors: H M Sandler; R L Dunn; P W McLaughlin; J A Hayman; M A Sullivan; J M Taylor Journal: Int J Radiat Oncol Biol Phys Date: 2000-10-01 Impact factor: 7.038
Authors: Jay P Ciezki; Chandana A Reddy; Jorge Garcia; Kenneth Angermeier; James Ulchaker; Arul Mahadevan; Nabil Chehade; Andrew Altman; Eric A Klein Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-06 Impact factor: 7.038
Authors: H Mermall; R B Sothern; E L Kanabrocki; S F Quadri; F W Bremner; B A Nemchausky; L E Scheving Journal: Urology Date: 1995-07 Impact factor: 2.649
Authors: Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun Journal: CA Cancer J Clin Date: 2006 Mar-Apr Impact factor: 508.702
Authors: Robert D Loberg; Jeffery R Fielhauer; Brian A Pienta; Scott Dresden; Patty Christmas; Linda M Kalikin; Karin B Olson; Kenneth J Pienta Journal: Urology Date: 2003-12-29 Impact factor: 2.649
Authors: Anthony V D'Amico; Judd W Moul; Peter R Carroll; Leon Sun; Deborah Lubeck; Ming-Hui Chen Journal: J Natl Cancer Inst Date: 2003-09-17 Impact factor: 13.506
Authors: Roberto L Muller; Joseph C Presti; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Stephen J Freedland Journal: Urology Date: 2012-03-23 Impact factor: 2.649
Authors: Douglas G McNeel; Heath A Smith; Jens C Eickhoff; Joshua M Lang; Mary Jane Staab; George Wilding; Glenn Liu Journal: Cancer Immunol Immunother Date: 2011-12-31 Impact factor: 6.968
Authors: Andrew S Chiang; D Andrew Loblaw; Vibhuti Jethava; Perakaa Sethukavalan; Liying Zhang; Danny Vesprini; Alexandre Mamedov; Robert Nam; Laurence Klotz Journal: Can Urol Assoc J Date: 2013 Nov-Dec Impact factor: 1.862
Authors: C J Paller; X Ye; P J Wozniak; B K Gillespie; P R Sieber; R H Greengold; B R Stockton; B L Hertzman; M D Efros; R P Roper; H R Liker; M A Carducci Journal: Prostate Cancer Prostatic Dis Date: 2012-06-12 Impact factor: 5.554
Authors: Lauren V Wood; Antonio Fojo; Brenda D Roberson; Meghan S B Hughes; William Dahut; James L Gulley; Ravi A Madan; Philip M Arlen; Marianna Sabatino; David F Stroncek; Luciano Castiello; Jane B Trepel; Min-Jung Lee; Howard L Parnes; Seth M Steinberg; Masaki Terabe; Julia Wilkerson; Ira Pastan; Jay A Berzofsky Journal: Oncoimmunology Date: 2016-07-01 Impact factor: 8.110
Authors: Guru Sonpavde; Mingjun Wang; Leif E Peterson; Helen Y Wang; Teresa Joe; Martha P Mims; Dov Kadmon; Michael M Ittmann; Thomas M Wheeler; Adrian P Gee; Rong-Fu Wang; Teresa G Hayes Journal: Invest New Drugs Date: 2013-04-23 Impact factor: 3.850